| Background and ObjectiveActive treatment of acute ischemic stroke in actue stage can be reduced to some extent, mortality and disability of stroke patients, but the incidence of the disease can not be reduced. Effective in reducing the harm, the fundamental measure is prevention. Long-term Scientific and Technological Development (2006-2020) clearly stated in the disease control center to forward, putting prevention first, combining health promotion and disease prevention, prevention-oriented health care strategy is welcomed by all,This study explores the regulating role of the dengzhan shengmai capsule for secondary prevention of ischemic stroke patients with MMPs, TIMPs and HDL-C, describes the role of the dengzhan shengmai capsule in secondary prevention of ischemic stroke. In order to explore the ideas of traditional Chinese medicine to prevent the recurrence of ischemic stroke mechanism.MethodsThe cases are from the hospital of traditional Chinese medical Guangdong provincial, the neurology one ward, the neurology three ward clinics patients and them's outpatients for the first time ischemic stroke patients. Standards consistent with research programs selected cases, according to randomized, controlled, double-blind clinical trial principles. The clinical trial is by divided into two groups. Experimental group:it is made up of the dengzhan shengmai capsule, basic treatment and behavioral intervention. Control group: it is made up of placebo capsule of the dengzhan shengmai capsule, basic treatment and behavioral interventions. Both groups are be treated continuous medication 12 months. Monitoring the indicators and point in time:the recurrence rate of ischemic stroke can be analyzed after 12 months of follow-up. Functional disability:The differences between the two groups with the mRS scores will be respectively evaluated by following up for 6 months,12 months. The differences between the two groups of patients before and after also are assessed by using rank sum test. MMP-2, TIMP-2, TIMP-2/MMP-2, MMP-9, TIMP-1, TIMP-1/MMP-9 the changes of blood-serum contents, respectively, will be assessed by the initiation of experiment and the end of experiment, It is also assessed to the difference between the two groups before and after. HDL-C changes which take place in the interclass and the interior groups, respectively will be analyzed by the initiation of treatment, followed up for 6 months, followed up for 12 months.,As the safety index, adverse events which happen in the groups are observed in the period of experiment. Statistical analysis uses SPSS 17.0 statistical analysis software. All the statistical tests are used two-sided test, P value less than 0.05 is as the statistically significant difference test. Statistical methods are Chi-square test with count data, measurement data with the t test, rank sum test using ranked data.ResultsIn the hospital of traditional Chinese medical Guangdong provincial, The neurology one ward, the neurology three ward clinics patients and them's outpatients were screened 415 cases. Finally, selected research program cases which meet the standards are 126,123 cases in which wards, out-patient in 3 cases.,The comparison of baseline data on the two groups was no significant difference, they might be comparable. In patients, the description of results which is the recurrence rate of secondary prevention is as:followed up for 12 months,7 cases of recurrence in two groups were happened. To March,2011, patients which completed the trial once again were on the telephone follow-up, there were 4 other cases of recurrence based on the original end point,2 cases of death due to ischemic stroke recurrence. Finally,11 cases were endpoint. The rate of recurrence was 8.73%,5 patients in trial group and control group 6 patients. Because it is a small probability event and the small sample size, no difference between the two groups is statistically described. The results of mRS score were as:followed up for 6 months and 12 months, there were no significant difference between the two groups (P> 0.05). But in the test group, there was significantly different between before and after the mRS score(P < 0.05).As time, mRS score was gradually decreased. MMP-2, TIMP-2, TIMP-2/MMP-2, MMP-9, TIMP-1, TIMP-1/MMP-9 of comparison:followed up 12 months, between the two groups, the six index had no difference in statistical significance(P> 0.05). But two groups before and after comparison:In MMP-2, TIMP-2, MMP-9, TIMP-1, TIMP-1/MMP-9, the experimental group and control group are significantly different than before (P<0.05). Before and after, the changes in the value of the experimental group TIMP-2/MMP-2 were no statistically significant difference (P>0.05), the changes in the value of the control group TIMP-2/MMP-2 were statistically significant difference (P < 0.05). The comparison of HDL-C:followed up for 6 months and 12 months, no significant difference happened between two groups (P> 0.05). But in the experimental group, there was significantly different between before and after the value of HDL-C by using paired t test (P<0.05). With chart 1 analysis, the experimental group compared with the control group, increasing HDL-C levels was evident. With time, the level of HDL-C values in the test group gradually increased. During the experiment, there were 12 cases of adverse events. The adverse events were disappearance or mitigation after symptomatic treatment.ConclusionThe dengzhan shengmai capsule can improve secondary prevention of ischemic stroke patients independent living, help to improve the quality of life of patients.The regulation of action of dengzhan shengmai capsule in the secondary prevention of ischemic stroke is the stable part of the role of serum TIMP-2/MMP-2 value, elevating serum levels of HDL-C. The role of action of dengzhan shengmai capsule in the secondary prevention of ischemic stroke is to maintain stability of matrix metalloproteinase-2 degrading the extra cellular matrix of the ability, conducive to the improvement lipid metabolism of patients.They are conducive to the stability of atherosclerotic plaques. These effectivenesses play roles in the prevention of ischemic stroke recurrence.
|
PDF Full Text Request